Trial Information
registHER: An Observational Cohort Study of Patients With HER2 Positive Metastatic Breast Cancer
Inclusion Criteria:
- Signed Informed Consent document (unless the IRB has granted a waiver of consent)
- Signed Authorization for the Use and Disclosure of Health Information document
- HER2-positive breast cancer
- Initial diagnosis of metastatic (Stage IV) breast cancer within 6 months prior to
enrollment
- Availability of cancer-specific historical data points in the patient's medical
records
Exclusion Criteria:
- There are no exclusion criteria for participation in this trial
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Principal Investigator
Isaiah Dimery, M.D.
Investigator Role:
Study Director
Investigator Affiliation:
Genentech
Authority:
United States: Institutional Review Board
Study ID:
H2757n
NCT ID:
NCT00105456
Start Date:
March 2003
Completion Date:
May 2009
Related Keywords:
- Breast Cancer
- HER2-Positive Metastatic Breast Cancer
- HER2
- Breast Neoplasms